Study of the Bioequivalence of the 20% and 30% Etoricoxib Tablet Formulations (0663-070)

• Status: Completed
• Trial end date: 2002-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will establish the bioequivalence of the 20%, milled, roller compaction final market image (FMI) etoricoxib tablets and 30% unmilled, roller compaction (UMC) etoricoxib tablets.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Etoricoxib

Criteria

Inclusion Criteria:

• Subject is in good health

• Subject agrees to follow the study guidelines

Exclusion Criteria:

• Subject is a smoker

• Subject has a history of adverse reactions caused by NSAIDs or allergies/intolerance to NSAIDs

• Subject is in a situation or has a condition/disease which may interfere with optimal participation in the study